Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
bristol-myers squibb
life sciences
national
national blog main
novartis
3
×
cancer
cancer immunotherapy
samit hirawat
acquisition
adaptimmune
allergan
allogeneic
alnylam
approval
bidding
bill newell
biological
blueprint
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
brad loncar
brent saunders
buyout
car-t
celgene
clinical study
common sense
democrats
detroit blog main
detroit top stories
donald trump
doug ingram
drug prices
eli lilly
fallout
fda
female
What
celgene
3
×
acquisition
anniversary
approaches
bn
bristol
chief
clinical
company’s
corporation
diversity
hirawat
medical
myers
myers’s
officer
pipeline
progress
scrip
spoke
squibb
trial
year
airport
annual
apocalypse
beds
days
fallout
gone
home
j.p
jpm
notes
price
sleep
staggers
time
vortex
Language
unset
Current search:
novartis
×
celgene
×
@xconomy.com
3 years ago
Bristol Myers’s Hirawat on Pipeline Progress, Clinical Trial Diversity
@xconomy.com
3 years ago
Bristol Myers’s Hirawat on Pipeline Progress, Clinical Trial Diversity
@xconomy.com
5 years ago
Notes from the JPM19 Vortex: Price Apocalypse, Celgene Fallout & More
